Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,915 recruiting studies in this area right now.
By phase
- Not applicable2,021
- Phase 21,071
- Phase 1792
- Phase 1/Phase 2476
- Phase 3346
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital42
Where studies are running
- California395
- Texas185
- Alabama156
- Maryland151
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,915 total
- NCT07519772RecruitingPhase 1/Phase 2
Testing MK-1045 for Hard-to-Treat Lymphoma
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT05947851RecruitingPhase 3
Nemtabrutinib plus venetoclax versus standard add-on therapy
This Phase 3 study tests whether adding nemtabrutinib to venetoclax works better than the usual next treatment approach (venetoclax plus rituximab) in people with relapsed or treatment-resistant CLL/SLL. It may help by improving how well the cancer responds after at least one prior therapy.
Springdale, ArkansasAges 18 years+ - NCT07027826Recruiting
String test for eosinophilic esophagitis in African patients
This study tests a new, less invasive way (the Esophageal String Test) to look for signs of eosinophilic esophagitis—an allergic condition that can make swallowing painful or difficult. It is for people of African descent who have trouble swallowing and are already having an endoscopy.
Bethesda, MarylandAges 18–65 - NCT07328516Enrolling by invitation
Farm childhood health study for adult children
This study looks at how early-life exposures on farms might influence long-term health. If you are an adult child of a farmer or farmworker from the Agricultural Health Study, and you spent time on a farm as a child, you may be able to join.
Bethesda, MarylandAges 18–99 - NCT05621291Recruiting
Sequencing test to guide care after CD19 CAR T in kids
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Los Angeles, CaliforniaAges 1–25 - NCT07643896Recruiting
Blood test for pregnancy risk assessment using fetal cells
This study tests a new blood test that looks for fetal cells in your bloodstream to check your baby's health during pregnancy. The test is non-invasive—just a regular blood draw—and aims to help identify pregnancy risks earlier than traditional methods.
Phoenix, ArizonaAges Any age - NCT06975865RecruitingPhase 3
Rilzabrutinib for sickle-cell disease pain episodes
This study tests an oral medicine called rilzabrutinib to see if it can reduce painful episodes in people with sickle-cell disease. It may be an option if you have regular pain crises and are looking for a new treatment.
Birmingham, AlabamaAges 10–65 - NCT05588167Recruiting
Niemann-Pick type C patient database and genetic data study
This study collects health information and genetic samples from people diagnosed with Niemann-Pick disease type C. The goal is to build a large database that can help researchers better understand the condition and improve future care.
Bethesda, MarylandAges 3 months+ - NCT07864701RecruitingPhase 1/Phase 2
Study of an experimental drug for MYC-positive advanced cancers
This trial tests an experimental drug (JMBI-001) for people with advanced cancers that have a specific marker called MYC. It aims to see if the drug is safe and effective, possibly shrinking tumors or slowing their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07775313Enrolling by invitationPhase 1/Phase 2
Gene therapy for WHIM syndrome
This trial tests a one-time gene therapy treatment for WHIM syndrome, a rare immune disorder. It aims to fix the genetic cause to improve your body's ability to fight infections. Your stem cells will be collected, edited in a lab, and given back to you after some chemotherapy to prepare your body.
Bethesda, MarylandAges 3–75 - NCT07825064RecruitingPhase 2
Cevostamab combination after CAR T-cell therapy for multiple myeloma
This trial tests a new drug, cevostamab, combined with two standard medicines (pomalidomide and dexamethasone) for people with multiple myeloma who have already had CAR T-cell therapy. It aims to see if this combination can help control the cancer better.
GreifswaldAges 18 years+ - NCT07634471RecruitingPhase 2/Phase 3
Testing MK-1045 and Rituximab for Untreated Follicular Lymphoma
This trial tests a new drug called MK-1045 combined with rituximab (a standard lymphoma treatment) in people who have never been treated for follicular lymphoma. The goal is to see if this combination works better than current treatments.
Duarte, CaliforniaAges 18 years+ - NCT07421167RecruitingPhase 2
Ianalumab with TPO-RA for immune thrombocytopenia
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Fayetteville, ArkansasAges 18 years+ - NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT02504853Recruiting
Study food allergy patterns and genetics over time
This study follows people with food allergy and some closely related or healthy people to learn how food allergy (and related conditions) develops over time. It may help researchers find causes and better ways to predict and treat food allergy.
Bethesda, MarylandAges 1 day–99 years - NCT07200089RecruitingPhase 1
IL-7 treatment after CAR-T therapy for multiple myeloma
This trial tests whether a drug called NT-I7 (a lab-made immune booster) can help people with multiple myeloma who have already received a CAR-T cell therapy called cilta-cel. It's for patients whose myeloma has come back or hasn't responded well to treatment.
St Louis, MissouriAges 18 years+ - NCT06919939RecruitingPhase 2
Epcoritamab and Loncastuximab for relapsed large B-cell lymphoma
This trial tests a combination of two targeted drugs (epcoritamab and loncastuximab tesirine) for people with large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if this combination can shrink tumors and improve outcomes.
Miami, FloridaAges 18 years+ - NCT07723703RecruitingPhase 1
Study of a new drug for acute myeloid leukemia and related blood cancer
This trial is testing a new medicine called AMX-883 for people with a type of blood cancer called acute myeloid leukemia (AML) or a high-risk blood disorder called myelodysplastic syndrome (MDS) that has come back or not responded to other treatments. The study hopes to see if the drug is safe and works, either alone or combined with another drug.
Fairfax, VirginiaAges 18 years+ - NCT07354074RecruitingPhase 2
Study of asciminib for children with Ph+ CML
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
New Brunswick, New JerseyAges 1–18 - NCT01821456Recruiting
Study of immune-suppressed people in Cologne
This study follows people whose immune systems are weakened (immunosuppressed). Researchers want to better understand what happens in this group, and what risks or outcomes may occur.
Cologne, North Rhine-WestphaliaAges 1 year+ - NCT02259556RecruitingPhase 1/Phase 2
CAR T treatment for CD30-positive lymphomas after standard therapies
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
Beijing, Beijing MunicipalityAges 16–80 - NCT02797717Recruiting
Treatment study for classical Hodgkin lymphoma in young people
This trial looks at a treatment approach for children and adolescents with classical Hodgkin lymphoma. It may help by testing how well the treatment controls the cancer and is tolerable in young patients.
Petah TikvaAges 1 month–18 years - NCT02869529Recruiting
Chronic lymphatic leukemia patient database study
This study collects information from people diagnosed with chronic lymphatic leukemia. It may help doctors better understand the disease, track patient needs, and improve future care.
Marseille, Bouches-du RhôneAges 18–95
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,915 recruiting hematology studies from the U.S. registry right now, out of 7,233 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.